Back to Screener

Financial Services

ProShares - Ultra Nasdaq Biotechnology(BIB)

Live Price

Offline

$98.28

+4.38% today

1Y Change

+114.54%

Window

Jun 30, 2025 โ†’ Jun 26, 2026

Market Cap
$70.00M
Revenue Growth
0.0%
EPS Growth
0.0%
Dividend Yield
0.0%

Coverage: 249 bars ยท Jun 30, 2025 โ†’ Jun 26, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

ProShares - Ultra Nasdaq Biotechnology (BIB) is a Financial Services stock with a market cap of $70.00M. The stock last traded around $98.28 and up 114.5% across the available one-year price window (Jun 30, 2025 โ†’ Jun 26, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of 0.0%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS 0.0%, free cash flow 0.0% with operating margin 0.0% and ROIC 0.0%. Stock Foundry combines BIB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Financial Services peers on this page.

Benchmark Edge

BIB vs SPY, QQQ, and Sector ETFs

Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.

Shared 1Y chart + MAX history table

Relative Read

Mixed setup vs SPY

BIB is 96.55 pts ahead over the shared 1Y window.

BIB had 7.79 pts deeper max drawdown than SPY.

BIB beat SPY in 2 of 2 calendar years shown and trailed in 0.

BIB

+114.54%

Normalized return

SPY

+17.99%

S&P 500

Excess Return

+96.55 pts

Relative to SPY

BIB Max Drawdown

-16.93%

Trailing 1Y

SPY Max Drawdown

-9.13%

Trailing 1Y

BIBSPY

Calendar-Year Returns

Uses the longest available daily history for BIB and SPY.

YearBIBSPYExcessLeader
2026+23.41%+6.71%+16.70 ptsBIB
2025+74.11%+11.19%+62.92 ptsBIB

Unable to load analyst forecasts.

Timed out loading forecasts for BIB

Next Step

Put consensus data in context

Forecasts are most valuable when they sit beside comparisons, earnings setup, and the rest of the business story.